LIVE NEWS
  • Kosovo president moves to dissolve Parliament for early election as country plunges into new crisis
  • Western Union Partners with Crossmint to Launch USDPT Stablecoin on Solana
  • Middle East crisis live: US submarine sank Iranian warship, Hegseth says; Israel launches fresh strikes on Tehran | US-Israel war on Iran
  • Calls for Global Digital Estate Standard as Fraud Risk Grows
  • An ode to craftsmanship in software development
  • Global economy must stop pandering to ‘frivolous desires of ultra-rich’, says UN expert | Environment
  • Some Middle East Flights Resume but Confusion Reigns From Iran Strikes
  • Clinton Deposition Videos Released in Epstein Investigation
Prime Reports
  • Home
  • Popular Now
  • Crypto
  • Cybersecurity
  • Economy
  • Geopolitics
  • Global Markets
  • Politics
  • See More
    • Artificial Intelligence
    • Climate Risks
    • Defense
    • Healthcare Innovation
    • Science
    • Technology
    • World
Prime Reports
  • Home
  • Popular Now
  • Crypto
  • Cybersecurity
  • Economy
  • Geopolitics
  • Global Markets
  • Politics
  • Artificial Intelligence
  • Climate Risks
  • Defense
  • Healthcare Innovation
  • Science
  • Technology
  • World
Home»Healthcare Innovation»Common pneumonia bacterium may fuel Alzheimer’s disease
Healthcare Innovation

Common pneumonia bacterium may fuel Alzheimer’s disease

primereportsBy primereportsFebruary 21, 2026No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
Common pneumonia bacterium may fuel Alzheimer’s disease
Share
Facebook Twitter LinkedIn Pinterest Email


A common respiratory bacterium that typically causes pneumonia and sinus infections may also play a role in Alzheimer’s disease. Researchers at Cedars-Sinai report that Chlamydia pneumoniae can persist in both the eye and the brain for years, where it may worsen the damage associated with Alzheimer’s. The findings, published in Nature Communications, suggest that addressing chronic infection and inflammation could open the door to new treatment strategies, including early antibiotic use and therapies designed to reduce inflammation.

For the first time, scientists showed that Chlamydia pneumoniae can travel to the retina, the light sensitive tissue at the back of the eye. Once there, it activates immune responses that are tied to inflammation, loss of nerve cells, and declining cognitive function.

“Seeing Chlamydia pneumoniae consistently across human tissues, cell cultures and animal models allowed us to identify a previously unrecognized link between bacterial infection, inflammation and neurodegeneration,” said Maya Koronyo-Hamaoui, PhD, professor of Neurosurgery, Neurology, and Biomedical Sciences at Cedars-Sinai Health Sciences University and the leading, senior author of the study. “The eye is a surrogate for the brain, and this study shows that retinal bacterial infection and chronic inflammation can reflect brain pathology and predict disease status, supporting retinal imaging as a noninvasive way to identify people at risk for Alzheimer’s.”

Higher Bacterial Levels Tied to Cognitive Decline

The research team analyzed retinal tissue from 104 people using advanced imaging, genetic testing, and protein studies. Participants included individuals with normal cognition, mild cognitive impairment, and Alzheimer’s disease.

People diagnosed with Alzheimer’s had much higher levels of Chlamydia pneumoniae in both their retinas and brains compared to those with normal cognition. Researchers also observed that greater amounts of the bacterium were associated with more severe brain damage and worse cognitive decline.

Elevated bacterial levels were especially common in individuals carrying the APOE4 gene variant, which is known to increase the risk of developing Alzheimer’s.

Infection May Accelerate Alzheimer’s Processes

To further test the connection, scientists examined human nerve cells in the lab and studied mice with Alzheimer’s disease. In both models, infection with Chlamydia pneumoniae led to increased inflammation, greater nerve cell death, and worsening cognitive problems. The infection also stimulated the production of amyloid-beta, the protein that builds up in the brains of people with Alzheimer’s.

The study was led in part by co-first authors Bhakta Gaire, PhD, and Yosef Koronyo, MSc.

“This discovery raises the possibility of targeting the infection-inflammation axis to treat Alzheimer’s,” said Timothy Crother, PhD, co-corresponding author of the study and research professor at Cedars-Sinai Guerin Children’s and the Department of Biomedical Sciences at Cedars-Sinai.

Overall, the findings indicate that treating long standing bacterial infections and the inflammation they cause could represent a new therapeutic approach. The results also strengthen the case for using the retina as a noninvasive tool to help detect and monitor Alzheimer’s disease.

Additional Cedars-Sinai authors include Bhakta Gaire, Yosef Koronyo, Jean-Philippe Vit, Alexandre Hutton, Lalita Subedi, Dieu-Trang Fuchs, Natalie Swerdlow, Altan Rentsendorj, Saba Shahin, Daisy Martinon, Edward Robinson, Alexander V. Ljubimov, Keith L. Black, Jesse Meyer, and Moshe Arditi.

Other authors include Julie A. Schneider, Lon S. Schneider, Debra Hawes, Stuart L. Graham, Vivek K. Gupta, and Mehdi Mirzaei.

Funding: This work has been supported by the NIH/NIA grants R01AG056478, R01AG055865, and AG056478-04S1 (M.K.H.), R01AG075998 (M.K.H. and T.R.C.), and Alzheimer’s Association grant AARG-NTF-21-846586 (T.R.C.). MKH is also supported by The Goldrich and Snyder Foundations. ER has been supported by The Ray Charles Foundation.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleBitcoin Sell Pressure Is Easing, But Whales Keep Dumping on Exchanges: CryptoQuant
Next Article France strikes to address misinformation weakening Western alliance
primereports
  • Website

Related Posts

Healthcare Innovation

Elevance stock tumbles as CMS may halt Medicare enrollment

March 3, 2026
Healthcare Innovation

Training harder could be rewiring your gut bacteria

February 25, 2026
Healthcare Innovation

GSK to buy 35Pharma, picking up lung disease drug

February 25, 2026
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Global Resources Outlook 2024 | UNEP

December 6, 20255 Views

The D Brief: DHS shutdown likely; US troops leave al-Tanf; CNO’s plea to industry; Crowded robot-boat market; And a bit more.

February 14, 20264 Views

German Chancellor Merz faces difficult mission to Israel – DW – 12/06/2025

December 6, 20254 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest Reviews

Subscribe to Updates

Get the latest tech news from FooBar about tech, design and biz.

PrimeReports.org
Independent global news, analysis & insights.

PrimeReports.org brings you in-depth coverage of geopolitics, markets, technology and risk – with context that helps you understand what really matters.

Editorially independent · Opinions are those of the authors and not investment advice.
Facebook X (Twitter) LinkedIn YouTube
Key Sections
  • World
  • Geopolitics
  • Popular Now
  • Artificial Intelligence
  • Cybersecurity
  • Crypto
All Categories
  • Artificial Intelligence
  • Climate Risks
  • Crypto
  • Cybersecurity
  • Defense
  • Economy
  • Geopolitics
  • Global Markets
  • Healthcare Innovation
  • Politics
  • Popular Now
  • Science
  • Technology
  • World
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Cookie Policy
  • DMCA / Copyright Notice
  • Editorial Policy

Sign up for Prime Reports Briefing – essential stories and analysis in your inbox.

By subscribing you agree to our Privacy Policy. You can opt out anytime.
Latest Stories
  • Kosovo president moves to dissolve Parliament for early election as country plunges into new crisis
  • Western Union Partners with Crossmint to Launch USDPT Stablecoin on Solana
  • Middle East crisis live: US submarine sank Iranian warship, Hegseth says; Israel launches fresh strikes on Tehran | US-Israel war on Iran
© 2026 PrimeReports.org. All rights reserved.
Privacy Terms Contact

Type above and press Enter to search. Press Esc to cancel.